Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451574 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL18985093 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL276114 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL2670965 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL1831666 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL14732171 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL7263751 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL276282 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL7259802 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL3307877 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | NANOSCIENCE FOR LIFE GMBH & COKG (DE) | 2019-03-26 | — | — | US | disclosed |
| US-20170121360-A1 | APPARATUS AND METHOD FOR OBTAINING GLYCOGLYCEROLIPIDS AND GLYCOSPHINGOLIPIDS FROM LIPID PHASES | GEA WESTFALIA SEPARATOR GROUP GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| EP-1896479-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006134485-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| US-6645671-B2 | Suppressing reaction between organic solvent and anode via imide compound which coordinates with lithium ions quickly and strongly, improving cycling; power sources for memory retention in electronics | FUJITSU LIMITED (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1158589-A1 | SECONDARY LITHIUM BATTERY, NEGATIVE ELECTRODE FOR SECONDARY LITHIUM BATTERY, AND PROCESS FOR PRODUCING THE NEGATIVE ELECTRODE | FUJITSU LIMITED (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-20010031396-A1 | Lithium secondary battery, anode for lithium secondary battery, and method for manufacturing the anode | FUJITSU LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-5998065-A | N-OXYIMIDE ADDITIVE | FUJITSU LIMITED (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0604957-B1 | 2-Amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5478808-A | Blood disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5478809-A | Blood disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0638588-A1 | Derivatives of 6,7-Dihydroxy-4-thiaheptonic acid and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0604957-A1 | 2-Amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0604945-A1 | TAN-1511, its derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121360-A1 | APPARATUS AND METHOD FOR OBTAINING GLYCOGLYCEROLIPIDS AND GLYCOSPHINGOLIPIDS FROM LIPID PHASES | AGL, LIPA, MGLL | FDPS 455/4885MAPT 4704/4885OPRM1 4754/4885 |
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | AGL, LIPA, MGLL | FDPS 455/4885MAPT 4704/4885OPRM1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.